...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases
【24h】

5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases

机译:具有抗增殖活性的5-取代的3-异丙基-7- [4-(2-吡啶基)苄基]氨基-1(2)H-吡唑并[4,3-d]嘧啶类化合物作为有力和选择性的细胞周期蛋白依赖性抑制剂激酶

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A series of 5-substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives was synthesized and evaluated for their cyclin-dependent kinase (CDK) inhibition activity. The most potent compounds contained various hydroxyalkylamines at the 5 position and possessed low nanomolar IC50 values for CDK2 and CDK5. Preliminary profiling of one of the most active compounds on a panel of 50 protein kinases revealed its high selectivity for CDKs. The compounds arrested cells in S and G2/M phases, and induced apoptosis in various cancer cell lines. Significant dephosphorylation of the C-terminus of RNA polymerase II and focal adhesion kinase (FAK), well-established substrates of CDKs, has been found in treated cells. Cleavage of PARP-1, down-regulation of Mcl-1 and activation of caspases correlated well with CDK inhibition and confirmed apoptosis as the primary type of cell death induced in cancer cells treated with the compounds in vitro. A comparison of known purine-based CDK inhibitor CR8 with its pyrazolo[4,3-d]pyrimidine bioisosteres confirmed that the novel compounds are more potent in cellular assays than purines. Therefore, pyrazolo[4,3-d]pyrimidine may emerge as a novel scaffold in medicinal chemistry and as a source of potent CDK inhibitors. (C) 2016 Elsevier Masson SAS. All rights reserved.
机译:合成了一系列5-取代的3-异丙基-7- [4-(2-吡啶基)苄基]氨基-1(2)H-吡唑并[4,3-d]嘧啶衍生物,并评估了它们的细胞周期蛋白依赖性激酶(CDK)抑制活性。最有效的化合物在5位上含有各种羟烷基胺,并且CDK2和CDK5的IC50值较低。对50种蛋白激酶中活性最高的化合物之一的初步分析表明,它对CDK具有很高的选择性。这些化合物将细胞停在S和G2 / M期,并诱导了各种癌细胞系的凋亡。已经在处理过的细胞中发现了RNA聚合酶II和粘着斑激酶(FAK)(CDK的成熟底物)的C端显着去磷酸化。 PARP-1的切割,Mcl-1的下调和胱天蛋白酶的激活与CDK抑制密切相关,并证实凋亡是在体外用该化合物处理的癌细胞中诱导的主要细胞死亡类型。将已知的基于嘌呤的CDK抑制剂CR8与吡唑并[4,3-d]嘧啶类生物甾体进行比较,证实了新型化合物在细胞分析中比嘌呤更有效。因此,吡唑并[4,3-d]嘧啶可能在药物化学中作为新型支架出现,并可能成为有效的CDK抑制剂的来源。 (C)2016 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号